Sleep Medications Compared: Zolpidem, Orexin Blockers, Trazodone and Melatonin

No sleep medication is best for everyone, and for chronic insomnia a medication is usually not the first step. The American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for all adults with chronic insomnia, and shared decision-making about short-term medication if CBT-I alone is not enough.

When a medication is used, the main FDA-approved choices are the "z-drugs" (zolpidem, eszopiclone, zaleplon), the orexin receptor blockers (suvorexant, lemborexant, daridorexant), low-dose doxepin, ramelteon, and a few benzodiazepines. Trazodone is FDA-approved for depression, not insomnia. Over-the-counter diphenhydramine and melatonin are widely used, but the American Academy of Sleep Medicine (AASM) suggests clinicians not use trazodone, diphenhydramine or melatonin for chronic insomnia.

The options side by side

The AASM's 2017 pharmacologic guideline gave weak recommendations for suvorexant, eszopiclone, zaleplon, zolpidem, triazolam, temazepam, ramelteon and doxepin, each compared with no treatment. Weak, in that system, reflects lower certainty, not proof that a drug fails. The guideline did not rate lemborexant or daridorexant.

Z-drugs: zolpidem, eszopiclone and zaleplon

Z-drugs are GABA-A receptor modulators that act on the same receptor system as benzodiazepines, though they are not benzodiazepines. Zolpidem is approved for short-term treatment of insomnia with trouble falling asleep and/or staying asleep. They are Schedule IV controlled substances.

On April 30, 2019, the FDA announced a boxed warning for eszopiclone, zaleplon and zolpidem after reports of sleepwalking, sleep driving and other activities done while not fully awake, some resulting in serious injury or death. The FDA also told prescribers not to use these drugs in anyone who has had a complex sleep behavior on one of them, and the labels list it as a contraindication. If such an episode happens, the label says to stop the drug immediately.

• Next-morning impairment: risk rises with dose and with other sedating drugs or alcohol, and the label cautions against driving the morning after use.
• Women: the extended-release zolpidem label recommends a lower starting dose for women than the higher option allowed for men. Your prescriber sets the dose.
• Older adults: the 2023 AGS Beers Criteria advise avoiding z-drugs, citing delirium, falls, fractures and car crashes with only minimal improvement in sleep.

Orexin receptor blockers: suvorexant, lemborexant, daridorexant

These drugs block receptors for orexin, a brain signaling system involved in wakefulness, which is thought to suppress the drive to stay awake. All three are approved for insomnia with difficulty falling asleep and/or staying asleep, and all three are Schedule IV. All three are contraindicated in narcolepsy.

Their labels warn about next-day impairment, including impaired driving, and about sleep paralysis, hallucinations at sleep onset or waking, cataplexy-like symptoms and complex sleep behaviors. All three labels also warn that depression or suicidal thinking may worsen. In a study of recreational drug users, suvorexant produced "drug liking" ratings similar to zolpidem, which is part of why it is controlled.

For people who wake in the middle of the night, an orexin blocker may be discussed as an alternative to a z-drug. That is a prescriber's judgment based on your history, other medicines and morning schedule.

Low-dose doxepin and ramelteon

Doxepin is an older antidepressant, but at very low doses it is approved specifically for insomnia with trouble staying asleep. The labeled doses are 3 mg and 6 mg, far below antidepressant doses, and it is not a controlled substance. The Beers Criteria treat doses above 6 mg a day as highly anticholinergic and best avoided in older adults, while noting that low-dose doxepin has a safety profile comparable to placebo. It cannot be taken with MAOIs.

Ramelteon acts on melatonin receptors and is approved for insomnia with trouble falling asleep. It is not a controlled substance and does not appear to produce physical dependence. The AASM suggests it for sleep onset insomnia, with a weak recommendation.

Trazodone: common, but off-label

Trazodone is FDA-approved for major depressive disorder in adults. Low doses are widely prescribed for sleep, but that use is off-label, and the AASM suggests that clinicians not use trazodone for sleep onset or sleep maintenance insomnia. That recommendation is weak, reflecting limited evidence rather than proven harm.

Like other antidepressants, trazodone carries a boxed warning about suicidal thoughts and behaviors in children and young adults. Its label also warns about prolonged erections (priapism), QT prolongation, low blood pressure on standing, bleeding risk with blood thinners or NSAIDs, and serotonin syndrome with other serotonergic drugs. Trazodone is sometimes considered when someone has both depression and insomnia, and our comparison of mirtazapine and trazodone covers that decision.

Benzodiazepines for sleep

Temazepam is approved for short-term treatment of insomnia, generally 7 to 10 days. Benzodiazepines carry a boxed warning that combining them with opioids can cause profound sedation, slowed breathing, coma and death, and that they carry risks of misuse, addiction, physical dependence and withdrawal reactions that can be life-threatening if stopped abruptly. The AASM gives temazepam and triazolam weak recommendations versus no treatment. Our guide to hydroxyzine vs benzodiazepines covers these drugs in more depth.

Over-the-counter antihistamines

Diphenhydramine, the active ingredient in common over-the-counter sleep aids, and doxylamine are first-generation antihistamines. A diphenhydramine sleep aid is labeled for occasional sleeplessness, and its Drug Facts tell you to stop and ask a doctor if sleeplessness lasts more than 2 weeks, since insomnia can be a symptom of an underlying illness. The label also says to ask a doctor first if you have glaucoma, a breathing problem or trouble urinating from an enlarged prostate, and to avoid alcohol.

The Beers Criteria describe first-generation antihistamines as highly anticholinergic, note that tolerance develops when they are used for sleep, and link cumulative anticholinergic exposure with falls, delirium and dementia, even in younger adults. The AASM suggests clinicians not use diphenhydramine for chronic insomnia.

Melatonin: what is in the bottle

In the United States melatonin is sold as a dietary supplement, which the FDA regulates less strictly than prescription or OTC drugs. The National Center for Complementary and Integrative Health says there is not enough strong evidence on melatonin's effectiveness or safety for chronic insomnia to recommend it, though it may help with jet lag.

Product quality is a real problem. A 2023 study in JAMA tested 25 melatonin gummy products: 22 were outside 10% of the labeled melatonin amount, one product contained no detectable melatonin, and in the rest actual content ranged from 74% to 347% of the label. Some products also contained CBD. If you use melatonin, tell your prescriber the product and amount, and keep gummies away from children.

What the evidence does not show

It is easy to read a comparison table and assume one drug has been proven better than another. The evidence does not support that level of confidence. The AASM rated every medication it recommended as weak, and explained that evidence quality was downgraded because most trials were industry-funded with a risk of publication bias, there were few eligible trials for each drug, and results varied between studies. It also stressed that a recommendation's strength says nothing about how large the benefit will be for a particular person.

For older adults, the Beers Criteria describe the improvement from z-drugs in time to fall asleep and total sleep as minimal compared with their risks. And for melatonin, the problem is not only weak evidence for chronic insomnia but uncertainty about the dose in the product itself. None of this means sleep medications never help. It means the benefit should be checked against a clear goal, and the medication reconsidered if that goal is not met.

Common mistakes that raise the risk

• Doubling up on antihistamines. The diphenhydramine sleep-aid label says not to use it with any other product containing diphenhydramine, even one applied to the skin. Combination cold, allergy and nighttime pain products can contain one too, so read the active ingredients on every label you use at night.
• Taking a z-drug without a full night ahead. The extended-release zolpidem label says to take it immediately before bed with at least 7 to 8 hours remaining before you plan to wake.
• Adding alcohol or other sedatives. Next-morning impairment rises with other CNS depressants and alcohol.
• Ignoring breathing problems. The suvorexant label asks prescribers to consider effects on respiratory function, and the OTC antihistamine label asks people with a breathing problem such as emphysema or chronic bronchitis to check with a doctor first.
• Stopping a benzodiazepine suddenly after regular use, which can trigger withdrawal reactions that may be life-threatening.
• Dismissing new mood changes. The orexin-blocker labels warn that depression or suicidal thinking may worsen, and any new behavioral change should be evaluated promptly.

If you are pregnant, planning pregnancy or breastfeeding, the choice involves different evidence; see psychiatric medications during pregnancy and talk with both your prescriber and obstetric clinician.

How the choice usually gets made

Insomnia that persists deserves a fresh look rather than a stronger pill. Several labels advise reevaluating if insomnia continues after 7 to 10 days of treatment, because it can signal another condition. Possibilities to rule out include sleep apnea, restless legs, depression, anxiety, pain and medication side effects; our article on when a sleep study helps explains the workup, and insomnia treatment options compared covers CBT-I in detail.

Questions to ask before starting a sleep medication

• Is my problem falling asleep, staying asleep, or both, and which option fits that pattern?
• Have we ruled out sleep apnea, restless legs or a medication side effect?
• Can I get CBT-I, alone or alongside a medication?
• How long should I take this, and how will we decide whether it is working?
• Is it a controlled substance, and what happens when I stop?
• Is it safe with my other medicines, alcohol and my morning driving?

Never stop or change a prescribed sleep medicine on your own, especially a benzodiazepine, where abrupt discontinuation can cause dangerous withdrawal.

How Dr. Lewis's practice approaches sleep medications

The practice's prescribers provide psychiatric evaluation and medication management, and its therapists provide psychotherapy including CBT; nutrition and lifestyle psychiatry are part of its ongoing care. That mix lets a sleep plan address mood, anxiety and habits together rather than adding a pill in isolation. The drlewis.com page on sleep disorders describes the practice's view of sleep problems, and medication management explains how prescribing visits work. More comparisons are in the Choosing Psychiatric Care guide.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Frequently asked questions

Which sleep medication is least habit-forming?

Low-dose doxepin and ramelteon are not controlled substances, and the ramelteon label says it does not appear to cause physical dependence. Z-drugs, orexin blockers and benzodiazepines such as temazepam are Schedule IV controlled substances. Habit-forming risk is only one factor; ask your prescriber which fits your sleep pattern.

Is it safe to take a sleeping pill with alcohol?

Alcohol adds to the sedation of z-drugs and other sleep medicines; the zolpidem label says next-morning impairment risk increases with alcohol. OTC sleep aids also tell you to avoid alcohol.

Can I take melatonin with a prescription sleep medicine?

Ask your prescriber first. Melatonin is a supplement with unreliable labeling, so you may not know how much you are taking.

Why did my doctor suggest CBT-I instead of a pill?

The American College of Physicians recommends CBT-I as the first treatment for chronic insomnia in adults, with a strong recommendation. It addresses the habits and thoughts that keep insomnia going.

Are orexin blockers safer than zolpidem?

They work differently and have a different warning profile, but they are also Schedule IV and can impair next-day driving. Neither class is safer for everyone.

How long can I stay on a sleep medication?

Labels differ. Zolpidem and temazepam are labeled for short-term use, while some newer drugs were studied for longer. Your prescriber should set a review date when you start.

Sources

1. Certain Prescription Insomnia Medicines: New Boxed Warning - Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake. U.S. Food and Drug Administration, 2019. fda.gov
2. Ambien CR (zolpidem tartrate extended-release) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
3. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults. Journal of Clinical Sleep Medicine (AASM; Sateia et al.), 2017. pubmed.ncbi.nlm.nih.gov
4. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine (Qaseem et al.), 2016. pubmed.ncbi.nlm.nih.gov
5. Belsomra (suvorexant) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
6. Quviviq (daridorexant) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
7. Dayvigo (lemborexant) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
8. Silenor (doxepin) tablets prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
9. Rozerem (ramelteon) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
10. Trazodone hydrochloride tablets prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
11. Restoril (temazepam) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
12. Vicks ZzzQuil Nighttime Sleep-Aid (diphenhydramine HCl) Drug Facts. DailyMed / FDA OTC label, 2026. dailymed.nlm.nih.gov
13. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 2023. pmc.ncbi.nlm.nih.gov
14. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA (Cohen et al.), 2023. pmc.ncbi.nlm.nih.gov
15. Melatonin: What You Need To Know. National Center for Complementary and Integrative Health (NIH), 2024. nccih.nih.gov
16. 21 CFR 1308.14 Schedule IV. Electronic Code of Federal Regulations (DEA), 2026. ecfr.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.